

The UK MS Pregnancy Register: Baseline data from the first 50 participants

Sarah White, Nicola Macleod (MS Clinical Nurse Specialists)
Peter Brex, Helen Ford, Stella Hughes, Katy Murray, Owen Pearson, David Rog, Ruth Dobson (Consultant Neurologists)
Priyanka Iyer (Academic Foundation Doctor)
Rod Middleton (System Architect) Elaine Craig (Research Analyst, UK MS Register)

Aims of the register


The UK MS Pregnancy Register was launched in 2021 with the aim of gathering information on the experience of pregnancy and the postpartum period for women with MS in the UK.

Data is collected through various questionnaires filled out by the participants during pregnancy and in the first year after giving birth.


We present baseline data on the **first 50 participants**.

Breaking news!

- As of February 2022, we currently have **65 participants** recruited on the MS Pregnancy Register.
- The map below shows the geographical location of the recruited participants.
- Why is it important to recruit participants?
 - To improve our evidence base for the safety of various DMTs and symptomatic therapies during pregnancy and breastfeeding
 - Gain an understanding of the choices that women with MS make during pregnancy and breastfeeding and how this impacts them.



Link to recruit participants



Results


Demographics:

- Mean age at diagnosis 28 years, mean current age: 33 years
- Ethnicity: British (80%), White - Other (10%), White and Asian (4%), White and Black Caribbean (2%), African (2%) and another ethnic group (2%)


MS and DMT specific data:

- All patients had **relapsing remitting MS**
- Median EDSS 2.5 (n=16)
- 90%** of patients had **ever taken DMT**.
- Of the patients that had stopped DMT (n=23), 39% stopped prior to pregnancy and 30% following conception.
- 22 women were currently taking DMT. Of these, **15 are continuing DMT during their current pregnancy**, 5 have decided to stop later on in pregnancy and 2 were undecided.

When did you have discussions about future pregnancies?



Whom did you discuss your future pregnancies with?




Pregnancy specific data:

- Gestation at recruitment : **2 to 40 weeks**
- 78%** had discussed their **pregnancy in advance** with their MS team.
- 84% were on Vitamin D in their current pregnancy
- In prior pregnancies, 61% (14/23) reported pregnancy loss.
- Other complications included PPH and foetal macrosomia (1), pre-eclampsia (1) and genetic condition in the baby (1).


DMT use in current pregnancy

- Glatiramer acetate
- Natalizumab
- Peginterferon beta-1a
- Not reported



Prior recorded DMT Use

- Glatiramer acetate
- Natalizumab
- Interferon beta-1a/ Peginterferon beta-1a
- Alemtuzumab
- Dimethyl fumarate
- Ocrelizumab



Conclusions

Our results show that a patient-facing pregnancy MS registry is feasible and can collect adverse previous pregnancy outcomes. Future results will inform clinicians and women about the safety of DMT and adjunctive medications during pregnancy and postpartum.